HCW Biologics Says It Received USPTO Notice Of Allowance For Claims Covering Use Of HCW9302 To Treat Alopecia Areata; Says Phase 1 Monotherapy Study On Track For Q4 2026 Completion

뉴스 본문을 불러오고 있어요.

HCW Biologics Says It Received USPTO Notice Of Allowance For Claims Covering Use Of HCW9302 To Treat Alopecia Areata; Says Phase 1 Monotherapy Study On Track For Q4 2026 Completion | 웨이프 WAPE

HCW Biologics Says It Received USPTO Notice Of Allowance For Claims Covering Use Of HCW9302 To Treat Alopecia Areata; Says Phase 1 Monotherapy Study On Track For Q4 2026 Completion

기사 요약

관련 종목

댓글 —